score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7023	393.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	20.0	0.4	1.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat118	MEL-IPI_Pat118-Tumor-SM-5X2QV	MEL-IPI_Pat118-Normal-SM-5X2RD
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	XIST--COL1A1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				XIST--COL1A1 Fusion	0.0	MEL-IPI_Pat118		
Investigate Actionability	Preclinical			Rearrangement	RUNX1	Fusion	XXYLT1--RUNX1			0.0	0.0		Investigate Actionability	Azacitidine + Panobinostat	Hypomethylating agent chemotherapy + HDAC inhibition	Combination therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				XXYLT1--RUNX1 Fusion		MEL-IPI_Pat118		
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P179S	0.3514	148.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	92.0	0.2717	1.0	PBRM1 p.P179S (Missense)		MEL-IPI_Pat118	MEL-IPI_Pat118-Tumor-SM-5X2QV	MEL-IPI_Pat118-Normal-SM-5X2RD
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.G112R	0.2778	18.0	0.0	0.0																Investigate Actionability	1.0	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	28.0	0.0	0.9192	RBM10 p.G112R (Missense)		MEL-IPI_Pat118	MEL-IPI_Pat118-Tumor-SM-5X2QV	MEL-IPI_Pat118-Normal-SM-5X2RD
Biologically Relevant				Rearrangement	PBRM1	Fusion	RP11-435B5.4--PBRM1			0.0	0.0																					0				RP11-435B5.4--PBRM1 Fusion		MEL-IPI_Pat118		
Biologically Relevant				Rearrangement	ERBB3	Fusion	MALAT1--ERBB3			0.0	0.0																					0				MALAT1--ERBB3 Fusion		MEL-IPI_Pat118		
Biologically Relevant				Rearrangement	ETV6	Fusion	HIPK2--ETV6			0.0	0.0																					0				HIPK2--ETV6 Fusion		MEL-IPI_Pat118		
Biologically Relevant				Rearrangement	AKT2	Fusion	CMTM3--AKT2			0.0	0.0																					0				CMTM3--AKT2 Fusion		MEL-IPI_Pat118		
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E37*	0.5789	19.0	0.0	0.0																					0	0.0	0.0	0.0	CDKN2A p.E37* (Nonsense)		MEL-IPI_Pat118	MEL-IPI_Pat118-Tumor-SM-5X2QV	MEL-IPI_Pat118-Normal-SM-5X2RD
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat118		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.68																									0				COSMIC Signature (version 2) 7 (68%)		MEL-IPI_Pat118		
